Skip to main content
NervGen Pharma Corp. logo

NervGen Pharma Corp. — Investor Relations & Filings

Ticker · NGEN ISIN · CA64082X2032 LEI · 549300CZ6Y0WSURPE203 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 325 across all filing types
Latest filing 2020-07-22 Regulatory Filings
Country CA Canada
Listing TSXV NGEN

About NervGen Pharma Corp.

https://nervgen.com/

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on the discovery and development of pharmaceutical treatments designed to promote nervous system repair following neurologic trauma and disease. The company's core mission is to enable the nervous system to repair itself, offering a pharmacologic approach to conditions previously considered irreparable. Its lead drug candidate is NVG-291, a novel therapy currently in Phase 1b/2a clinical trials (CONNECT SCI Study) for individuals living with chronic spinal cord injury (SCI). Recent study data has demonstrated durable improvements in function and quality of life in this patient population. NervGen is also advancing its next-generation candidate, NVG-300, into preclinical proof-of-concept studies for three initial indications, expanding its pipeline for nervous system disorders.

Recent filings

Filing Released Lang Actions
Marketing materials - English.pdf
Regulatory Filings
2020-07-22 English
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a press release announcing a research collaboration and grant award related to a preclinical study on spinal cord injury. It contains no financial statements, regulatory filings, or detailed financial data. It is not an annual or interim report, earnings release, or any form of regulatory filing. It is a corporate news announcement about a research grant and collaboration, which does not fit into any of the specific financial or regulatory filing categories. Therefore, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2020-06-22 English
Report of exempt distribution excluding schedule 1 of Form 5 (amended).pdf
Regulatory Filings
2020-06-04 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the granting of stock options to directors, officers, consultants, and employees. It details the number of options, exercise price, vesting periods, and compliance with TSX Venture Exchange policies. There is no financial report, earnings data, or detailed management discussion. The content is about a capital-related update specifically concerning stock options granted, which fits the category of Capital/Financing Update (CAP). The document length is short and it is not an announcement of a report publication or a regulatory filing. Therefore, the classification is Capital/Financing Update (CAP) with high confidence.
2020-06-03 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings Classification · 100% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed instructions and fields related to filing reports of exempt distributions under Canadian securities regulations. It includes references to filing requirements with Canadian securities commissions, details about issuers, underwriters, and investment funds, and instructions on how to report distributions exempt from prospectus requirements. This form is a regulatory filing used to report exempt distributions of securities, not a financial report, earnings release, or management discussion. It is a compliance document filed with securities regulators to disclose exempt distributions, fitting the category of Regulatory Filings (RNS). The document is lengthy and detailed, but it is not an annual report, audit report, or any other financial statement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-06-02 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings Classification · 100% confidence The document is titled 'Form 45-106F1 Report of Exempt Distribution' and contains detailed instructions and fields related to filing reports of exempt distributions under Canadian securities regulations. It includes references to filing requirements, issuer information, underwriter information, and specific securities codes. The document is a regulatory form used to report exempt distributions of securities, which is a compliance filing rather than a financial report or announcement of financial results. It does not contain financial statements, earnings data, or management discussion. It is not an announcement of a report but the report form itself. This type of filing fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit into other specific categories.
2020-06-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.